Sugi Predict

Sugi Predict / Compounds / SCHEMBL2515799

SCHEMBL2515799

SCHEMBL2515799

CC(=O)N[C@H](C(=O)O)C(C)(C)C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA2 P00918 2/20 0.42
▸ MAPT P10636 2/20 0.41
▸ KDM4E B2RXH2 2/20 0.41
▸ THRB P10828 2/20 0.41
▸ RECQL P46063 2/20 0.41
▸ ALOX15 P16050 1/20 0.41
▸ NFKB1 P19838 1/20 0.41
▸ PTGS2 P35354 1/20 0.41
▸ THPO P40225 1/20 0.41
▸ BLM P54132 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ ALDH1A1 P00352 4/20 0.40
▸ ADAM17 P78536 1/20 0.35
▸ PYGL P06737 1/20 0.31
▸ CYP2C9 P11712 1/20 0.31
▸ PTGS1 P23219 2/20 0.31
▸ CNR2 P34972 1/20 0.31
▸ MMP12 P39900 1/20 0.30
▸ CYP1A2 P05177 1/20 0.30
▸ MMP2 P08253 3/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8415890 1.00 CA2 (0.42) CA2MAPTKDM4ETHRBRECQL
SCHEMBL1236539 1.00 CA2 (0.42) CA2MAPTKDM4ETHRBRECQL
SCHEMBL8357912 0.82 CA2 (0.43) CA2MAPTTHRBRECQLALDH1A1
SCHEMBL883447 0.82 CA2 (0.43) CA2MAPTTHRBRECQLALDH1A1
SCHEMBL12965979 0.82 ADAM17 (0.36) CA2MAPTKDM4ETHRBRECQL
SCHEMBL23155068 0.82 ADAM17 (0.36) CA2MAPTKDM4ETHRBRECQL
SCHEMBL25893507 0.81 KDM4E (0.39) CA2MAPTKDM4ETHRBRECQL
N-Acetyl Penicillamine SCHEMBL4468919 0.81 MAPT (0.43) CA2MAPTKDM4ETHRBRECQL
N-Acetyl Penicillamine SCHEMBL521764 0.81 MAPT (0.43) CA2MAPTKDM4ETHRBRECQL
N-Acetyl Penicillamine SCHEMBL34351 0.81 MAPT (0.43) CA2MAPTKDM4ETHRBRECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115894143-B Palladium catalyzed double ligand unguided preparation method for deuterated aromatic compound 宁波萃英化学技术有限公司 2024-05-28 — — CN claimed
CN-117209522-A Preparation method of multi-substituted aromatic compound containing alkyne and amine functional groups 广东工业大学 2023-12-12 — — CN claimed
US-12441762-B2 Hepatitis c virus NS3/4A protease inhibitors UNIVERSITY OF MASSACHUSETTS (US) 2025-10-14 — — US disclosed
CN-115894143-B Palladium catalyzed double ligand unguided preparation method for deuterated aromatic compound 宁波萃英化学技术有限公司 2024-05-28 — — CN disclosed
CN-113861228-B Alkyl borane derivative and synthesis method thereof 齐鲁工业大学 2023-10-24 — — CN disclosed
US-20230312542-A1 HYDROXYPYRROLIDINE DERIVATIVE AND MEDICINAL APPLICATION THEREOF MITSUBISHI TANABE PHARMA CORPORATION (JP) 2023-10-05 — — US disclosed
CN-115894143-A Palladium-catalyzed double-ligand non-guide preparation method of deuterated aromatic compound 宁波萃英化学技术有限公司 2023-04-04 — — CN disclosed
US-20230099018-A1 HEPATITIS C VIRUS NS3/4A PROTEASE INHIBITORS UNIV MASSACHUSETTS (US) 2023-03-30 — — US disclosed
EP-4129402-A1 HYDROXYPYRROLIDINE DERIVATIVE AND MEDICINAL APPLICATION THEREOF Mitsubishi Tanabe Pharma Corporation (JP) 2023-02-08 — — EP disclosed
CN-111362985-B Water-soluble cyclic tetranuclear palladium (II) complex and preparation method and application thereof 昆明贵研新材料科技有限公司 2022-11-29 — — CN disclosed
US-11472778-B2 Hepatitis C virus NS3/4A protease inhibitors UNIVERSITY OF MASSACHUSETTS (US) 2022-10-18 — — US disclosed
EP-1917269-B1 INHIBITORS OF SERINE PROTEASES VERTEX PHARMA (US) 2011-10-26 — — EP disclosed
US-20110244530-A1 L-SUCCINYLAMINOACYLASE AND PROCESS FOR PRODUCING L-AMINO ACID USING IT TOYO BOSEKI KABUSHIKI KAISHA (JP) 2011-10-06 — — US disclosed
US-20110195940-A1 Protease Inhibitors Having Enhanced Features NEKTAR THERAPEUTICS (CA) 2011-08-11 — — US disclosed
US-20030078436-A1 Process for the catalytic preparation of N-acylglycine derivatives GEISSLER HOLGER (DE) 2003-04-24 — — US disclosed
EP-0918745-B1 CATALYTIC PREPARATION PROCESS OF N-ACYLGLYCINE DERIVATIVES AVENTIS RES & TECH GMBH & CO (DE) 2001-11-28 — — EP disclosed
US-20010007911-A1 CATALYTIC PREPARATION PROCESS OF N-ACYLGLYCINE DERIVATIVES AVENTIS RESEARCH & TECHNOLOGIES DEUTCHLAND GMBH & CO. KG. (DE) 2001-07-12 — — US disclosed
EP-0918745-A1 CATALYTIC PREPARATION PROCESS OF N-ACYLGLYCINE DERIVATIVES Aventis Research & Technologies GmbH & Co KG (DE) 1999-06-02 — — EP disclosed
WO-1998004518-A1 CATALYTIC PREPARATION PROCESS OF N-ACYLGLYCINE DERIVATIVES AVENTIS RESEARCH & TECHNOLOGIES GMBH & CO KG (DE) 1998-02-05 — — WO disclosed
US-3996288-A Method of producing aldehydes by hydroformylation AJINOMOTO CO., INC. (JA) 1976-12-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010007911-A1 CATALYTIC PREPARATION PROCESS OF N-ACYLGLYCINE DERIVATIVES ACACA, ACOX1, APEH CA2 1026/4885MAPT 4847/4885KDM4E 3776/4885
US-11472778-B2 Hepatitis C virus NS3/4A protease inhibitors HAVCR2, CTSC, DPP4 CA2 4694/4885MAPT 2763/4885KDM4E 782/4885
US-12441762-B2 Hepatitis c virus NS3/4A protease inhibitors HAVCR2, CTSC, DPP4 CA2 4694/4885MAPT 2763/4885KDM4E 782/4885
US-20230312542-A1 HYDROXYPYRROLIDINE DERIVATIVE AND MEDICINAL APPLICATION THEREOF VHL, MDM2, NEDD4 CA2 2903/4885MAPT 2776/4885KDM4E 655/4885
US-20110195940-A1 Protease Inhibitors Having Enhanced Features CYP3A43, HPN, ANPEP CA2 4472/4885MAPT 1834/4885KDM4E 2163/4885
US-20230099018-A1 HEPATITIS C VIRUS NS3/4A PROTEASE INHIBITORS HAVCR2, CTSC, DPP4 CA2 4694/4885MAPT 2763/4885KDM4E 782/4885
US-20030078436-A1 Process for the catalytic preparation of N-acylglycine derivatives GNMT, ALKBH3, DDC CA2 446/4885MAPT 4720/4885KDM4E 614/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.